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INTRODUCTION 
Thyroid disorders are the second most common endocrinologic disorders in 
pregnancy. Hypothyroidism is mainly caused by a primary abnormality in the 
thyroid, although a few cases are caused by hypothalamic dysfunction also. In 
pregnant or postpartum women, the most common causes are chronic /subacute 
autoimmune thyroiditis (Hashimoto's thyroiditis)(26), iodine deficiency, radioactive 
iodine therapy or  surgical removal of thyroid gland. 
Iodine deficiency is the   commonest   cause. Hashimoto’s thyroiditis is a 
common cause in industrialized nations. Overt hypothyroidism occurs in 0.3 to 0.5 % 
and subclinical in 2-3% of patients. Post partum thyroiditis reportedly affects 4-10% 
of women. 
Auto immune thyroiditis occurs during the first postpartum year. They can 
present with hypothyroidism or thyrotoxicosis followed by hypothyroidism. 
Thyroid hormone is essential for normal  development of the placenta. There is 
evidence that preeclampsia, placental abruption and preterm labour are causally 
linked to faulty early placentation. Thyroid hormone is also important for neuronal 
migration ,synaptic transmission and myelination during early  
neurodevelopment. The only assumed physiological role of iodine is thyroid  
hormone synthesis. Severe deficiency in iodine which causes hypothyroidism is  
found to be associated with decreased intelligence, cretinism and even  congenital 
anomalies of the fetus. Intra uterine growth restriction and fetal  
distress are more common in women with significant hypothyroidism. 
  
These complications can be prevented if thyroxine treatment is started in 1st 
trimester(ideally prenatally).Treatment after 1st trimester will not eliminate already 
established fetal neurodevelopmental delay, because it is in the first  
trimester that the fetus depends completely on maternal thyroid hormone for 
 brain development. 
Thyroid function tests need to be interpreted with caution because of the  
changes in thyroid physiology during pregnancy. The cutoff values for diagnosing 
thyroid dysfunction in pregnant women is not the same as non pregnant women. The  
diagnosis of hypothyroidism is also difficult in pregnancy because many of the 
symptoms and signs are common to both. Severe  hypothyroidism associated with 
pregnancy is uncommon because most of  these women will be infertile and they also 
have higher rates of miscarriages. 
There are not enough studies in  pregnant women with hypothyroidism to see if 
early thyroxine  supplementation  and adequate treatment actually reduces the 
occurrence of complications. This study was undertaken to see if promptly 
 diagnosed and adequately treated hypothyroid women were able to avert  
complications. 
 
 
 
 
REVIEW OF LITERATURE 
Historical background 
  
Goitres (Latin- guttur), defined as enlargement of the thyroid gland have been 
recognised since 2700 BC. The term thyroid gland (Greek- thyreoeides, shield 
shaped) was however coined by Thomas Wharton in 1656.It was thought to have 
various functions ranging from acting as a reservoir of blood to provide continuous 
supply to brain to beautifying women’s neck. Seaweed was considers as a treatment 
for goitre. In 1909, Kocher was awarded Nobel Prize for his work on the  pathology, 
and surgery of the thyroid gland. 
William Gull, Governor of Guy’s Hospital, in 1874  was the first to describe 
myxedema and  what he called a “cretinous state in the adult”.In  1883, Dr. Dawtrey 
Drewitt presented a patient with  the classical symptoms of hypothyroidism  in the 
Clinical Society of London 
The earliest oral treatment for hypothyroidism consisted of thyroid extract.  
The first treatment of hypothyroidism  with thyroid extract in 1891, was described by 
George Redmayne Murray in UK. The first recorded American use was as early as  
1891 by a woman who was taking it till  84 years of age. 
 
 
 
 
Embryology 
Around the third week of gestation the thyroid gland arises as a primitive out 
pouching of the primitive foregut. It originates at the base of tongue near the foramen 
caecum. Endodermal cells in the pharyngeal anlage thicken to form the medial 
  
thyroid anlage. This descends in the neck anterior to the hyoid bone. During this 
descent the thyroid anlage remains connected to the foramen caecum by the 
thyroglossal duct. The thyroid follicular cells arise from the epithelial cells of the 
thyroid anlage. The fourth brachial pouch gives rise to the paired lateral analages 
which fuse with the medial thyroid anlage. The lateral analages are neuroectodermal 
in origin and secrete calcitonin. Colloid formation begins in the thyroid follicles by 
11th week of gestation. 
 
Thyroid physiology 
Iodine metabolism and increased Iodine requirement in pregnancy: 
The average daily iodine requirement is 0.1mg. Fish, milk, eggs and iodised 
salt are rich sources of iodine. In the stomach and jejunum iodine is rapidly converted 
to iodide and absorbed into the blood stream. Iodide actively enters the thyroid 
follicular cells by an ATP dependent process. Thyroid stores nearly 90% of body’s 
iodine. The excess plasma iodine is excreted through the kidneys. 
The WHO recommends a daily intake of 250mcg of iodine for pregnant and 
lactating women because the increase in thyroid hormone production in pregnancy 
requires an equal increase in iodine availability. 
D3(placental deiodinase ) removes iodine from T3 & T4,generating  inactive 
iodothyronines and reverse T3.This also prevents large amounts of  T4 from crossing 
the placenta. Another reason for increase in iodine demand is increased GFR with an 
increased urinary clearance of iodine. Although the fetal thyroid starts developing  by 
12 wks of gestation, it cannot organify iodine till 20wks of gestation. Till that period 
  
the maternal T4 is the only form of the  hormone that can cross the placenta. 
Deiodinase  enzyme in the fetus converts maternal fT4 to T3 in brain & other tissues. 
So the fetal iodine store solely demands on maternal intake during this period. 
 
Thyroid hormone synthesis, secretion and transport: 
The first step in the synthesis of thyroid hormone is iodide trapping. It is an 
ATP dependent active transport across the basement membrane of the thyroid 
follicular cells. The thyroid follicles contain thyroglobulin (Tg) which is a 
glycoprotein with four tyrosyl residues. The second step in the synthesis of thyroid 
hormones involves  iodide oxidation  to iodine followed by  iodination of  tyrosyl 
residues on the thyroglobulin. Both processes in this step are catalysed by thyroid 
peroxidase. The end products of the second step are mono and  and diiodotyrosine 
(MIT&DIT). The third step involves their  coupling  to form tetraiodothyronine (T4) 
or one monoiodotyrosine and one diiodotyrosine molecule to form triiodothyronine 
(T3) or reverse triiodothyronine (rT3). Hydrolysis of the thyroglobulin molecule to 
release free iodothyronines (T3and T4) and mono and diiodotyrosines is the fourth 
step. The later are deiodinated in the fifth step yielding iodide which is reused by the 
thyrocyte. 
  
 
Fig : THYROID HORMONE SYNTHESIS, SECRETION AND TRANSPORT 
Thyroid hormones are transported in serum bound to thyroxine binding 
globulin (TBG), thyroxine binding prealbumin (TPBA) and albumin. Only a small 
fraction of thyroid hormone is free and this is the physiologically active hormone. T3 
is three to four times more potent than T4. The circulating levels of T3 are much 
lower when compared to T4 and is less tightly bound to proteins. Hence it enters 
  
tissues more easily.  T3 has a half life of one day while T4 has a half life of seven 
days. 
In euthyroid state T4 is released entirely by the thyroid gland while only 20% 
of T3 is released by thyroid. The remaining 80% of T3 is produced by deiodination of 
T4 in liver, kidneys and muscles. 
 
Metabolism and excretion of thyroid hormone: 
Metabolic inactivation of T3 occurs by glucuronide conjugation and de 
iodination. Liver is the primary site although salaivary glands and kidneys also play a 
role. The conjugates are excreted in bile. A major fraction is deconjugated in the 
intestines and re absorbed by entero hepatic circulation to be finally excreted in urine. 
 
Mechanism of action: 
T3 penetrates cells and combines with a nuclear receptor . Certain specific DNA 
sequences have been identified in regulatory regions of specific genes. The T3 
receptor complex binds to these specific DNA sequences leading to derepression or 
in some cases direct activation of gene transcription resulting in expression of 
predetermined pattern of protein synthesis. 
Many of the clinical manifestations of thyroid hormone like tachycardia, 
hypertension, arrhythmias, tremor, hyperglycaemia are mediated partly if not 
completely by sensitisation of adrenergic receptors to catecholamines.  
 
Functions of thyroid hormones: 
  
Thyroid hormones enter the cells by diffusion and binding of thyroid hormones to the 
nuclear receptors of cells results in translation and transcription of hormone specific 
genes. They affect almost every system in the body. 
They play an important role in fetal brain and skeletal development.  
 
Growth and development: 
Its role in growth and development can be understood by its action on the 
metamorphosis of tadpole to frog. Its action cannot be labelled catabolic or anabolic. 
It exerts a critical control over protein synthesis. Deficiency of thyroid hormone 
mainly affects the nervous system in early life. In cretinism there is retardation and 
nervous deficit as a result of paucity of synapse formation axonal and dendritic 
ramification and reduced myelination. In adult overt hypothyroidism also there is 
impairment of intelligence and movements are slow. 
 
Intermediary metabolism: 
Thyroid hormones have an important role in carbohydrate, lipid and protein 
metabolism. 
 
Carbohydrate: 
They stimulate carbohydrate metabolism. Although utilisation of carbohydrates 
is increased due to an increase in BMR, gluconeogenesis and glycogenolysis 
compensate for it. So hyperglycaemia and a diabetic like state occur in hyper 
thyroidism. 
  
 
Protein: 
The overall effect of T4 is catabolic. Negative nitrogen balance and tissue 
wasting result from prolonged action. This explains the weight loss in 
hyperthyroidism and weight gain in hypothyroidism. Thyroid hormones inhibit 
mucoprotein synthesis in low concentrations which characteristically accumulates in 
myxedema. 
 
Lipid: 
T4 and T3 indirectly enhance lipolysis although lipogenesis is also stimulated. 
Cholesterol metabolism is accelerated but its conversion to bile acids dominate. Thus 
hypocholesterolemia is a feature of hyperthyroidism and hypercholesterolemia and 
obesity are features of hypothyroidism. 
Calorigenesis: 
Basal metabolic rate is increased by stimulation of cellular metabolism and 
resetting of the energystat. But the metabolic rate in uterus, gonads, brain, spleen and 
lymph nodes is not significantly affected. The mechanism is uncoupling of oxidative 
phosphorylation thus releasing excess enegy as heat. 
 
Cardio vascular system: 
Heart rate, contractility and output are increased which cause a fast and 
bounding pulse. Thyroid hormones act on the contractile elements of the heart and 
stimulate them by upregulation of beta adrenergic receptors. They have a positive 
  
inotropic and chronotropic effect . Actions of catecholamines are augmented. That is 
why fibrillation and arrhythmias are common in hyperthyroidism. It can also 
precipitate angina. Blood pressure particularly systolic is often raised. Myocardial 
oxygen consumption can be markedly reduced by induction of hypothyroidism. 
 
Nervous system: 
They maintain the normal hypoxic and hypercapnic drive in the respiratory 
centre of brain .Mental retardation is the hallmark of cretinism. Sluggishness and 
other behavioural features are seen in myxedema whereas tremors, anxiety and 
hyperreflexia are seen in hyperthyroidism. 
 
Skeletal muscle: 
Thyroid hormones increase the protein turnover and speed of muscle 
contraction and relaxation .Myxedema is characterised by flabby and weak muscles 
while thyrotoxicosis causes an increase in muscle tone, tremor and weakness due to 
myopathy. 
 
Gastro intestinal system: 
Thyroid hormones increase gastric motility. Hypothyroid patients are often 
constipated while diarrhoea occurs in hyperthyroidism.  
 
Kidneys: 
  
They have no effect in euthyroid individuals but cause diuresis when myxedematous 
patients are treated with them. 
 
Haemopoiesis: 
Anaemia occurs in hypothyroid individuals, thus it is proven that T4 plays a role in 
erythropoiesis.  
 
Reproduction: 
Oligomenorrhoea and subfertility/infertility is known to occur in women with 
hypothyroidism. Normal functioning of the thyroid gland  is essential for 
maintenance of pregnancy and lactation. 
 Thyroid Physiology in Pregnancy: 
Pregnancy is associated with  changes in  thyroid physiology in the mother. 
Thyroid hormone is derived from iodination of tyrosine residues in thyroglobulin to 
form mono or di iodo tyrosine which are then coupled to form T4 and T3. The 
majority of T4 that is released is bound to circulating transport proteins  thyroxine 
binding pre albumin and albumin, thyroxine binding globulin (TBG ). The free 
fraction represents 0.04% of total T4 and is the physiologically active hormone or 
free T4. Anterior pituitary secretes TSH which increases the synthesis and release of 
thyroid hormone. 
  
During pregnancy there is an increase in estrogen mediated production of 
TBG.The increased binding of thyroid hormone together with its increased 
  
metabolism by the placenta leads to a greater requirement for thyroid hormone 
production in order to maintain free T4 levels. Total T4 levels are above the normal 
non pregnant levels. There is also an increase in renal clearance of thyroid hormone 
in pregnancy. All these along with increase in placental transfer of iodine to the fetus 
in turn results in increased maternal demand for iodine which is necessary for thyroid 
hormone production. Women who have borderline iodine deficiency may be unable 
to meet this increased demand resulting in reduction in thyroid hormone production. 
 
HCG belongs to a family of glycoprotein hormones which also includes TSH 
with a common alpha subunit and unique beta subunit. However there is considerable 
homology between beta subunits of human chorionic gonadotropin and TSH. So 
HCG has weak TSH like  activity 
 
Serum thyrotropin (TSH) level in early pregnancy is decreased because of 
thyroid stimulation from the weak TSH effects of HCG. So there is also a slight 
increase in free T4 levels. There are pregnancy conditions associated with higher than 
usual HCG levels such as a molar gestation, hyperemesis gravidarum or multiple 
gestation. These may result in an exaggerated stimulation of the thyroid gland and 
transient first-trimester thyrotoxicosis. TSH will rebound to normal nonpregnant 
levels once HCG returns to a steady state. So there will be a mild decline in free T4 
and an increase in TSH after the first trimester. But these changes typically remain 
within the reference range. That is why FT4 and TSH levels should be interpreted 
after comparison with specific reference ranges for each trimester   
  
 
 
 
 
 
 
Fig: MATERNAL THYROID HORMONE LEVELS IN PREGNANCY
 
 
  
 
  
Cut off values for TSH in pregnancy: 
In normal pregnancy,because of the suppressive effect of increasing thyroxin 
and increased TSH excretion, TSH is kept at its lowest minimal level  or can even go 
below normal range. In populations defined as euthyroids in various studies, TSH 
level is always 0.1-1.6 mIU/ml and  thyroxin level 
is increased one and half times in pregnancy In a study by Spencer et al in 2005,  
S.TSH >2.5 mIU/ml in 1st trimester showed T4 insufficiency(7). 
 
In a study by Green WL in 2005, truly normal range of TSH is defined as 0.5-
2.5mIU/ml(6) 
 
Adequate replacement therapy should be given when TSH is above 3mIU/ml 
and/or with low T4, FT4 in pregnancy. Prof. Ladenson has rightly said, this  should 
be considered as Gestational hypothyroidism. 
 
Thyroid physiology in the fetus and neonate: 
The human fetus starts to concentrate iodine and to synthesise hormone 
between 8 and 10 weeks of gestation along with the synthesis of TSH from the 
pituitary. Even though the pituitary thyroid axis is completely developed at 12 to 14 
weeks of gestation its function is minimal until a sudden surge in the fetal TSH 
occurs at 20 weeks. The fetal TSH levels continue to increase till 28 weeks after 
which it reaches a plateau and remains at the same level till term. Free T4 
  
concentration increases progressively till term and exceed maternal levels. Hence 
some level of fetal hyperthyroidism exists at term. 
                                Fig: FETAL THYROID PHYSIOLOGY 
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Weeks of pregnancy 
T4 is the major fetal thyroid hormone and the level of T3 is quite low 
throughout the gestation. However the levels of RT3 are elevated paralleling the rise 
of T4. During delivery the fetus goes from a state of relative T3 deficiency to T3 
thyrotoxicosis. Shortly after birth the TSH values rise rapidly and later falls to the 
baseline values by 48-72 hours. In response the T4 and T3 levels increase and reach 
the peak values by 24-48 hours and 24 hours of age respectively. The thyroidal 
hyperactivity takes about 3-4 weeks to completely disappear. 
 
The above changes occur mainly due to TRH surge as a response to rapid 
neonatal cooling since the TSH surge is accompanied by a prolactin surge. These 
thyroid changes are believed to be a protective mechanism against sudden entry of 
  
the foetus into the cold environment. The high RT3 levels during gestation return to 
the baseline at 2 weeks after reaching peak levels during the first 72 hrs of life.   
 
 
 
 
  
  
 
 
 
Fig: THYROID HORMONE LEVELS IN THE NEW BORN 
 
 
 
 
 
 
 
Summary of fetal and newborn thyroid changes: 
  
 
 TSH and T4 start appearing at 10-13 wks of gestation. 
 Levels reach an abrupt rise at 20 wks 
 T4 rapidly rises and exceeds maternal values at term 
 T3T3 values rise, but levels are relatively low, similar to hypothyroid adults 
 RT3 values exceed normal adult values 
 The fetal pattern of  low T3 and high RT3 is similar to the levels seen in calorie 
deprivation 
 After birth, TSH peaks at 30mins, followed by a T3 peak at 24 hrs and T4 peak at 
24hrs. 
 High RT3 values persist for 3-5 days after birth, then plateau down to normal values 
by 2 wks  
  
Maternal Hypothyroidism: 
                              Causes of Hypothyroidism 
Autoimmune Hashimoto thyroiditis 
 De Quervian's thyroiditis 
Iatrogenic Thyroidectomy 
 Previous radio-iodine treatment 
 Drug therapy(eg.lithium,amiodarone) 
Congenital hypothyroidism Thyroid agenesis 
 Thyroid dyshormonogenesis 
Iodine deficiency (most common cause) 
Infiltrative disorders Sarcoidosis 
 
Overt Hypothyroidism: 
This is characterised by an elevated TSH and  low Thyroxine levels.The 
incidence of overt hypothyroidism in pregnancy is 0.3-0.5%(12) 
 
The adverse effects include miscarriages, anaemia, pre-eclampsia, abruption, 
PPH, premature birth, LBW, increased neonatal respiratory distress.(12) 
In a study by Jones WS et al in the American Journal of Obstetrics and 
Gynaecology in 1969 a conclusion was made that premature deliveries were more 
frequent in pregnant women who had low thyroxine levels. 
  
In a study by Leung AS et al in 1993 it was found that overt hypothyroidism 
resulted in an increase in incidence of gestational hypertension, preeclampsia and low 
birth weight babies. (14) 
 
In a study Allan WC et al in 2000 it was concluded that fetal demises were 
significantly increased in patients with TSH greater than 10mIU/ml. 
 
Davis et al 1988 followed 25 hypothyroid women through 28 pregnancies who 
were divided into two groups, of which 16 were clinically hypothyroid and 12 had 
subclinical hypothyroidism. This study showed that mothers with overt 
hypothyroidism are more at risk for preeclampsia, preterm delivery, placental 
abruption, stillbirth, postpartum haemorrhage and cardiac-dysfunction 
 
ACOG practice bulletin on thyroid disease in pregnancy(2001) states that 
untreated  hypothyroid patients are at a increased risk of pre eclampsia and  
inadequate treatment is also associated with low birth weight infants.(26) 
 
In an Indian study by Sahu MT et al published in Archives of gynaecology and 
obstetrics in 2010, it was noted that IUGR ,gestational hypertension and IUD were 
increased in women with overt hypothyroidism. 
 
  
A couple of studies have shown low thyroxine concentration in early 
pregnancy can be associated with low intelligent quotient of children at 7 years of 
age. 
 
Ohara N et al in 2004 reviewed the literature on the role of thyroid hormone in 
trophoblast function and fetal neurodevelopement. They concluded that close scrutiny 
of maternal thyroid hormones to ensure adequate  hormone levels in early pregnancy 
are of prime importance in preventing miscarriage and neurodevelopmental deficits  
in infants(15) 
 
A study by Evelyn  Man and colleagues in 1969 compared the outcomes of 
1252  normothyroxinemic  pregnancies with 168 hypothyroxinemic pregnancies.30 
out of the 168 hypothyroid women  ended up having preterm deliveries or fetal 
death(19.6%) compared only12.6 % in the euthyroid group. 
 
Only few reports are available on the pregnancy outcome in hypothyroid 
pregnant women who are left untreated. These data show that adequate thyroxine 
replacement greatly improves but does not totally suppress the frequency of obstetric 
complications.(8) 
 
 
 
Subclinical Hypothyroidism: 
  
By definition,it is a condition in which TSH is elevated ,but FT4  is normal. 
Incidence of subclinical hypothyroidism is at least 2.5% .Usually it is asymptomatic, 
but there is evidence  autoimmune thyroid disease (positive TPOAbs and or TG 
antibodies)in 50-60%(12) Subclinical hypothyroidism was found to be more common  
in women delivering before 32 weeks.(12) 
 
Pregnancies complicated by subclinical hypothyroidism had a 3 fold increased 
risk of developing  placental abruption and 2 fold increased risk of preterm labour  
compared to euthyroid women.(22)Gestational hypertension also occurred more 
commonly in these women.(23) 
 
Even raised maternal TSH (high level of normal) is associated with neonatal 
respiratory distress, miscarriage and preterm delivery(12).The likelihood of patients 
diagnosed as hypothyroids during pregnancy to  continue to be hypothyroid even 
after pregnancy depends on the initial TSH value.The United States Preventive 
Services Task force reported that nearly almost all patients with an initial TSH >10 
mIU/ml developed overt hypothyroidism within 5 years.(33) 
 
 
 
Isolated Hypothyroxinaemia: 
It is defined as a condition with normal TSH and low fT4.Cleary Goldman  and 
colleagues in 2008 screened  10,990 patients for thyroid dysfunction .They noted that 
  
the presence of this isolated hypothyroxinemia  in 1st trimester was associated with an 
increased occurrence of preterm delivery and and macrosomia.Its occurrence in 2nd 
trimester was  associated with gestational diabetes.(28) 
 
Clinical features of hypothyroidism: 
Hypothyroidism developing in childhood   results in delayed development and 
may even cause abdominal distension, umbilical hernia and rectal prolapse. Mental 
performance is diminished but severe retardation is uncommon. In adults mostly 
symptoms are non specific. They include weight gain, fatigue,  intolerance to cold, 
constipation and menstrual irregularities like  menorrhagia. Patients with   myxedema 
have typical  facial features. Skin is yellowish due to reduced conversion of carotene 
to vitamin A. Hair becomes brittle and there is also a characteristic loss of the outer 
two third of eye brow. Untreated patients can develop dementia which is called 
myxedema madness. There is decreased libido and fertility in both sexes. Cardio 
vascular changes include bradycardia, pericardial or pulmonary effusions.  
 
 
Treatment of Hypothyroidism: 
Levothyroxine 
  
Levothyroxine or T4, is a synthetic form of 
normally secreted by the thyroid  
chiral L-form. Edward Calvin Kendall
its pure form from extracts of hog thyroid glands in 1914
synthesised  by British chemist 
Absorption of L thyroxine is incomplete varying from 50
therapeutic  purposes L thyroxine is superior to lio thyronine because of its longer 
duration of action. The only accepted indication for the use of  lio 
myxedema coma where a quick response is essential. 
 
Levothyroxine should be  taken on an empty stomach approximately half an 
hour  before meals. 
 
Patients should avoid taking 
taking thyroxine as these can interfere with the absorption of this drug. 
 
According to the American Thyroid Association,pregnant women  already 
being treated with thyroxine hormone often require a 30
 
the thyroid hormone
follicular cells .  Levothyroxine is chemically in the 
  of the Mayo clinic first isolated thyroxine in 
.The hormone was 
Charles Robert Harington  in 1927.
 
calcium and iron supplements within 4 hours
-50% increase in dose.The 
 , which is 
 
-70%. For most 
thyronine is 
 of 
 
  
need for the increase in dose starts as early as 5 weeks of gestation. The association 
urges physicians to be vigilant in identifying and treating women with subclinical 
thyroid dysfunction before conception. 
 
The Journal of Clinical Endocrinology and Metabolism  published an 
Executive Summary  which stated that,in patients with overt hypothyroidism the dose 
of thyroxine should be adjusted  to reach a TSH not more than 2.8 IU/ml 
periconceptionally. The Thyroxine  dosage  usually needs to be increased by 4-6 wks  
of gestational age and may require a 30-50% increase. If a patient is diagnosed to 
have overt hypothyroidism during pregnancy, titrate the  dose rapidly to keep the 
TSH at a level less than 2.5 IU/ml in the first trimester and less than 3 IU/ml in 
second and third trimesters. The panel recommends also  thyroxine  replacement in 
women with subclinical hypothyroidism. 
 
 
 
 
Complications of hypothyroidism in pregnancy: 
 Spontaneous abortion 
 Pregnancy induced hypertension(pre eclampsia, eclampsia) 
 Placental abruption 
 IUGR 
 Oligohydramnios 
  
 Preterm delivery 
 Fetal distress 
 Low birth weight 
 
 
 
 
 
 
 
 
 
 
 
 
 
Congenital Hypothyroidism: 
Congenital Hypothyroidism (CH) is one of the most common preventable 
causes of mental retardation. The  incidence is 1:4000 livebirths and the  worldwide 
and the incidence in India is 1:2500-2800 live births.  
 
Thyroid dysgenesis is the commonest cause attributing for the majority of 
cases. CH can be permanent or transient. Maternal cytotoxic antibodies and genetic 
  
mutations causing inactivation of thyroid receptor can be a cause.There is clinical and 
scientific evidence that hypothyroxinemia  causes poor neurodevelopment outcome 
in the children of mothers with low thyroxine levels. 
 
In a study by  Morreale de Escobar et al in2004,it was noted that thyroid 
hormone accumulates  in the cerebral cortex before 20 weeks.(30) 
 
Primary evidence of the effect of the deficiency of thyroid hormone on cerebral 
cortex was studied by Lavado-Autric et al in 2003.(31) 
 
Defects in thyroid hormone synthesis  account for 10% of all cases. These 
can be inherited as autosomal recessive disorders. Pharoah et al did a landmark study 
in 1971 and came to a conclusion that iodine supplementation in pregnancy prevented 
subsequent cretinism. 
Early and aggressive treatment with thyroxine is crucial for infants with 
congenital hypothyroidism. Yet some infants with prompt replacement exhibit mild 
cognitive defects in adolescence.(47) 
 
CLINICAL FEATURES OF CONGENITAL HYPOTHYROIDISM 
Untreated severe congenital hypothyroidism leads to irreversible growth failure 
and mental retardation 
 Early symptoms include feeding problems, constipation, growth failure and 
hoarse cry 
  
 Later they develop dry skin and decreased growth of nails and hair; tooth 
eruption is delayed 
 Closure of anterior and posterior fontanellesis delayed 
 Cardiomegaly may be present 
 
The other clinical features are broad, flat nose, pseudohypertelorism, puffy, 
myxedematous facies, large, protruding tongue, prolonged neonatal jaundice, 
protuberant abdomen, umbilical hernia 
 
  
  
Postpartum Thyroiditis: 
Postpartum thyroiditis is a characterized by a lymphocytic infiltration of the 
thyroid gland .It’s reported incidence is  in about 5% of pregnancies(17).It usually 
occurs in the 1st month after delivery.It starts as a thyrotoxic  phase followed by a 
phase of hypothyroidism lasting for months.It is typically characterized by the 
presence of TPO antibodies although it’s occurrence is women without these 
antibodies has also been reported.The risk is even greater when TPO antibodies are 
detected antenatally.Studies have shown that as many as 50% of women who 
developed postpartum thyroiditis continued to remain hypothyroid at the end of the 
1st postpartum year. There is no compelling evidence to support the early treatment of 
this condition. 
 
Thyroid antibodies: 
 These tests do not determine the thyroid function, instead they indicate the 
underlying disorder. Antithyroglobulin, antimicrosomal and thyroid stimulating 
immunoglobulin are the thyroid antibodies. Approximately 80% of patients with 
Hashimoto’s thyroiditis have raised thyroid antibody levels. 
 
 Thyroid peroxidase( TPO)antibodies and AntiThyroglobulin(TG) antibodies are 
linked to  pregnancy complications. There are  studies to show that euthyroid women 
with recurrent miscarriages and preterm birth were found to have antibodies to either 
TPO or TG.TPO antibodies have also been implicated  in the development of 
postpartum thyroiditis. 
  
 
  Association between auto immune thyroiditis and adverse obstetric outcome 
independent of thyroid function has also been proven in another prospective study  
where euthyroid TPO antibody positive women who received  thyroxine 
supplementation  in early pregnancy had a reduced rate of  miscarriage and preterm 
delivery rate(12) 
 
 Pregnant women with TPO antibodies were found to have a three times more chances 
of placental abruption when compared with antibody negative controls in a study  by 
Abbassi-Ghanavati et al in 2010. 
 
 Pop et al revealed decrease in the intelligent quotient of children aged 5 years whose 
mothers were TPO antibody positive  at 32 weeks of gestation even though they were 
actually euthyroid.(4) 
 
 Some thyroid autoantibodies  cross the placenta  causing  fetal thyroid dysfunction. 
But maternal Hashimoto thyroiditis is not typically found to be associated with fetal 
thyroid abnormalities. 
 
 Brown and co-workers in  1996 did a study on over one million babies and found that 
only 1 in 180,000 neonates born to mothers with Hashimotos thyroiditis had thyroid 
dysfunction.(46) 
 
Hypothyroidism and Infertility: 
  
Infertility is  defined as the inability to conceive after one year of intercourse 
without contraception (39) 
 
In mild degrees of hypothyroidism, ovulation and conception can occur, but 
the pregnancies that result are complicated by abortions, stillbirth or prematurity 
(13).On the other hand, severe hypothyroidism is commonly associated with 
ovulatory dysfunction and, thus,  infertility. Hypothyroid women can  present  with 
menstrual irregularities, especially oligomenorrhoea. 
 
Thyroid underfunction can also act more indirectly, by altering the HPO  axis, 
by reducing the binding activity of sex hormome-binding globulin (SHBG)causing an 
increase in serum free testosterone and estradiol, by decreasing the metabolic 
clearance of androstenedione and estrone. Also, TRH is elevated in  hypothyroidism 
which causes an increase in prolactin levels, and a delay in  LH release  to LH-
releasing  hormone (LHRH). Treatment of thyroid underfunction with L-thyroxine 
(L-T4) usually restores a normal menstrual pattern and  alleviates these pathological 
mechanisms (34) 
It has been recently recognised that disturbances of cognition and mood  develop in 
association with alteration in thyroid metabolism in the brain. There are even few 
small studies to show the connection  between thyroid dysfunction and mood 
disorders like  postpartum depression . 
 
Thyroid Dysfunction and pregnancy loss: 
  
 
Normal thyroid function is critical for normal functioning of the gonadal axis, 
thus important in maintaining normal reproduction.  
 
Gonadal steroid synthesis by oocytes depends on an adequate level of thyroid 
hormones. T3 modulates the regulating action of LH and FSH on steroid 
biosynthesis, thyroid hormones increase and enhance estrogenic responses(9). 
Dysthyroidism is associated with anovulatory cycles, subfertility or infertility 
Abortion rate as high as 60% in inadequately treated overt hypothyroids and 70% in 
subclinical hypothyroids(10) 
 
Matsua et al showed that Free T3 and Free T4 values  were significantly lower 
in women whose pregnancies terminated in abortions .(40) 
Donmez M et al in 2005 did a case control study to investigate thyroid dysfunction as 
an causative factor for  abortions. They performed thyroid function tests in 60 
patients having spontaneous miscarriages   and compared them with those of 40 
pregnant women of same gestational age who were presumed  to reach term. They 
found that T3 and T4 values were significantly lower and TSH values were 
significantly higher among the abortion group suggesting that subclinical 
hypothyroidism may be responsible for the spontaneous abortions(16) 
 
There are theories that consider autoimmune thyroiditis a consequence  of 
increased lymphocytes T activation. Patients with antecedents of habitual abortions 
  
show an increased number of endometrial T lymphocytes. Expression of the 
antithyroid antibodies may be an epiphenomenon that reflects an autoimmune 
imbalance, causing the rejection of the product of conception. This hypothesis is 
supported by the existence of an increased CD5/20 lymphocyte  positivity  in women 
with recurrent miscarriage(11) 
 
In 1990 Stagnaro- Green et al showed that among 552 women who were screened 
for thyroid antibodies , abortion  rate of 17% was observed in antibody positive group 
as compared to 8.4% in anti body negative group.(18) 
 
Bussen Steck et al in 1995 screened 22 non pregnant women with bad obstretic 
history for thyroid antibodies and detected a higher prevalence of thyroid antibodies 
in 36%  compared to 9% in multiparous controls and 5% in nulliparous controls.(19) 
 
Matalon ST et al in 2001showed that elevated levels of thyroid autoantibodies  are 
associated with increased rate of abortions in euthyroid women.(20) 
 
Vaquero et al in 2000 studied pregnancy outcomes in patients with mild thyroid 
abnormalities. Women mild thyroid abnormalities had an increased rate of 
miscarriage.  Thyroid replacement therapy with intra-venous immunoglobulins 
(IVIG) was helpful in preventing a new miscarriage (37)  
 
  
A study by Pratt et al found that the incidence of anti-thyroid antibodies in women 
who had repeated abortions were noticeably  higher than other non-organ-specific 
auto-antibodies(38) 
 
 
 
 
 
 
 
 
 
Screening for thyroid dysfunction during pregnancy: 
For universal screening to be recommended for a disease, 
 The incidence of the disease should be high enough to warrant screening. 
 The screening needs to be  as cost effective as possible 
 There should be substantiative  evidence that adverse outcomes are associated with 
the disease. 
 There should also be evidence that intervention improves outcomes. 
The journal of clinical endocrinology and metabolism adopted a clinical practise 
guideline in 2007 which  recommended  screening  among the following  high risk  
women(27) 
  
a) Women with a previous  history of hyper /hypo thyroid disease / thyroid 
ectomy/goitre 
b) Women with family history of thyroid dysfunction 
c) Women with symptoms/signs suggestive of thyroid dysfunction 
d) Women with  autoimmune diseases like Type 1 DM 
e) Women with a history of  infertility 
f) Women with history of head and neck irradiation 
g) Women with history of recurrent  miscarriages or preterm deliveries .        
 
 
 
According to the ACOG Committee Opinion no.381(oct 2007) also thyroid 
screening  in pregnancy should be carried out  only on symptomatic women / those 
with a  history of thyroid disease or other medical illnesses  that may be  associated 
with thyroid disease (eg:diabetes ) 
 
In a study by Bijay Vaidya et al published in JCEM in 2007,they found that   
thyroid function testing of only high risk  women  would miss about 1/3rd  of  women 
with overt/subclinical hypothyroidism.(21)                                                                             
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
 
Primary Aim:  
To assess the benefits and pregnancy outcome in promptly diagnosed and 
adequately treated antenatal hypothyroid women. 
 
Secondary Aims: 
To assess whether unfavourable pregnancy outcome and complications are 
more among the antenatal women  who are diagnosed late in pregnancy and hence 
inadequately treated. 
 
    
 
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 To measure pregnancy outcomes in all the study subjects, all antenatal women in 
their first trimester (first booking) or if they have their first visit only in second 
trimester will be screened with serum TSH. If TSH is more than 3miu/ml, they will 
be started on treatment after doing an FT4.They will be monitored to see if their 
treatment is adequate by repeating a serum TSH again in 2nd and 3rd trimesters. These 
women will be followed up till term and watched for any complications. Finally, they 
will be analysed to see if there is a significant increase in complications in the 
antenatal women who were diagnosed and started on treatment late and whether these 
complications could have been avoided if they were to be started on treatment early 
in the course of pregnancy 
 
       
 
  
 
 
 
 
 
 
 
 
Inclusion Criteria: 
a) All first and second trimester antenatal women with singleton gestation which 
will include overt hypothyroid women who are already on treatment(who have 
been informed about the study and who are willing to pay for the blood test) 
 
b) Women with subclinical hypothyroidism (elevatedTSH, normal fT4)     
 
 
 
Exclusion Criteria: 
Multiple gestation 
 
 
 
 
  
 
 
 
 
 
ESTIMATION OF FREE T3 
Method 
RIA ( Radio Immuno Assay ) – IMMUNOTECH Prague, Czech republic 
 
Principle 
The radio immuno assay of the free tri-iodo thyronine (T3) is a competitive 
assay done by using  labeled antibody. Samples and calibrators are incubated with an 
125I- labelled  antibody specific for T3, as tracer, in tubes coated with an analog of T3      
( ligand ). The free    tri-iodo thyronine and the ligand compete for the binding  to the 
labeled antibody. The content in the tubes is aspirated after incubation and bound 
radioactivity is measured. A calibration curve is designed and  values are ascertained 
by interpolation from the curve. 
 
Reagents 
 Ligand-coated tubes  
 
125I- labeled monoclonal antibody  
 Calibrators  
 Control serum 
  
 
 
 
 
Specimen collection 
Blood was collected in dry tubes or in tubes containing EDTA, in a fasting 
state. Serum/Plasma was separated from cells by centrifugation. Samples were stored 
at 2-80C. 
 
Results 
Normal range of Free T3 was taken as  2.5 – 5.8 pM/L. 
 
ESTIMATION  OF  FREE T4 
Method  
RIA (Radio Immuno Assay) 
Principle, Reagents and procedure are similar to Free T3 estimation. 
 
Results 
Normal range of  Free T4 was taken as  11.5 – 23 pM/L. 
 
ESTIMATION OF  TSH 
Method 
  
Solid Phase Two-Site ImmunoRadoMetric Assay ( IRMA ) with IRMAK-9 kit, 
BRIT, Mumbai. 
 
 
Principle  
In IRMA, two antibodies generated against different portions (epitopes) of the 
same antigen are used. One of the antibodies is bound to a solid phase, while the 
other  is labeled with 125I. Thus, the  antigen  binds both antibodies in a “sandwich” 
fashion. The radioactivity in the bound fraction is quantitated using a gamma counter.  
 
Reagents 
 hTSH monoclonal antibody coated tubes 
 
125I- Anti hTSH 
 Wash diluents  
 Control 
 
Specimen  collection 
Serum or plasma can be used for assay. 
EDTA plasma is not used. 
 
Results 
Normal range of TSH was taken as 0.17 – 3 µU/ml.      
 
  
 
 
Statistical Method: 
      The statistical package which was used for doing the analysis was SPSS 16.00 
version . Raw data were analysed using cross tabulations and Chi square test 
 
OBSERVATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Less than 20 yrs
20 - 25 yrs 
26 - 30 yrs 
More than 30 yrs
Total 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
Below 20 yrs
TABLE – I 
AGE DISTRIBUTION 
Frequency 
 5 
39 
58 
 24 
126 
20-25 yrs 26-30 yrs Above 30 yrs
Age
Percent 
4.0 
31.0 
46.0 
19.0 
100.0 
 
  
 
 
 
 
 
 
                      
 
 
 
 
 
50.80%
 
Primi 
Multi 
Total 
TABLE - II 
Obstetric Score 
49.20%
Obsetric Score
Frequency Percent 
62 49.2 
64 50.8 
126 100.0 
 
Primi
Multi
  
GESTATIONAL AGE AT 
 
Preconceptional
Less than 10 weeks
More than 10 weeks
Total 
 
 
This table shows the gestational age at which hypothyroidism was diagnosed
 
0 5
More than 10 weeks
Less than 10 weeks
Preconceptional
GESTATIONAL  AGE  AT  DIAGNOSIS
TABLE - III 
DIAGNOSIS 
Frequency Percent
 36 28.6
 45 35.7
 45 35.7
126 100.0
 
10 15 20 25 30 35 40
 
 
 
 
 
 
 
45
  
 
 
 
 
 
 
This table shows the levels of TSH in mIU/ml at the time of diagnosis. Most of 
the diagnosed hypothyroid patients had TSH levels between 5 and 10mIU/ml 
                                         TSH AT DIAGNOSIS
0 20
More than 10
5 to 10
3 to 5
 
3 to 5 
5 to 10 
More than 10
Total 
TABLE- IV 
TSH AT DIAGNOSIS 
 
 
 
 
40 60 80
Frequency Percent
8 6.3 
97 77.0
 21 16.7
126 100.0
 
 
100
 
 
 
 
  
ADEQUATE OR INADEQUATE TREATMENT
 
 
Adequate treatment
Inadequate treatment
Total 
 
This table shows that out of the 126 patients in our 
adequate treatment and 67 received inadequate treatment.
 
 
 
 
 
53.20%
TABLE -V 
Frequency Percent
 59 46.8 
 67 53.2 
126 100.0
study group 59 received 
 
46.80%
Adequate or Inadequate
Adequate
Inadequate
 
 
 
 
  
NUMBER OF  PATIENTS  WITH  COMPLICATIONS
 
 
 
 
 
 
 
 
 
 
 
 
60.30%
Complication
 
Yes 
No 
Total 
TABLE – VI 
 
39.70%
Yes
No
Frequency Percent
50 39.7 
76 60.3 
126 100.0 
 
 
  
TABLE – VII 
LIST OF COMPLICATIONS 
 
  
 
 
 
 
 
 
 
 
 
 
This table shows the profile of complications encountered in our patients 
 
 
 
 
 
 
 
 
2nd trimester abortion 1 
Blighted ovum 1 
Chronic HTN 1 
PIH 11 
Incomplete abortion 2 
IUGR 5 
Missed Abortion 3 
No 78 
oligohydramnios 8 
Preterm delivery 15 
  
TABLE - VIII 
MODE OF DELIVERY 
 
Frequency Percent 
Elective LSCS 15 12.60 
Emergency LSCS 32 26.89 
Forceps delivery 1 0.84 
NVD 42 35.29 
Preterm delivery 15 12.60 
Vacuum 14 11.78 
Total 119 100.00 
 
This table shows the modes of delivery of patients in our study group. Out of 
the 126 patients 7 had first trimester abortions and the modes of delivery of the 
remaining 119 patients are enlisted here. 
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TABLE-  IX 
GESTATIONAL AGE AT DELIVERY 
 Frequency Percent 
Less than 37 wks 15 12.6 
More than 37 wks 104 87.3 
Total 119 100 
 
This table shows that 15 out of the 126 patients had a preterm delivery before 
37 weeks of gestation. 
 
 
 
 
 
 
0 20 40 60 80 100 120
Less than 37 weeks
More than 37 weeks
GA at delivery
  
TABLE - X 
Crosstabulation between complication in the adequate and inadequate 
treatment groups 
 
 
 
Chi square value 35.872.p value<0.01 
Significance value 0.000 
This table shows that 64.2% of the inadequately treated patients developed 
complications while only 11.9% of the adequately treated group developed 
complication which was statistically significant,  
 
 
 
 
 
 
Complication 
Total 
Yes No 
 
Adequate 
Rx 
 7 52 59 
% 11.9% 88.1% 100.0% 
Inadequate
Rx 
 43 24 67 
% 64.2% 35.8% 100.0% 
Total 
Number 50 76 126 
% 39.7% 60.3% 100.0% 
  
 
TABLE - XI 
PREVALANCE OF GESTATIONAL DIABETES IN HYPOTHYROID 
PATIENTS 
 
 Frequency Percent 
GDM on diet 7 58.33 
GDM on insulin 5 41.66 
Total 12 100.0 
 
In my study 12 out of the 126 hypothyroid patients also had gestational 
diabetes mellitus , prevalence rate of 9.5% 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
TABLE - XII 
Complication  
Adequate 
Total 
Adequate Inadequate 
2nd trimester abortion 
No 1 0 1 
% 1.7% .0% .8% 
Blighted ovum 
No 0 1 1 
% .0% 1.5% .8% 
Chronic HTN 
No 1 0 1 
% 1.7% .0% .8% 
PIH 
No 1 10 11 
% 1.6% 14.9% 8.7% 
Incomplete abortion 
No 0 2 2 
% .0% 3.0% 1.6% 
IUGR 
No 0 5 5 
% .0% 7.4% 4.0% 
Missed Abortion 
No 0 3 3 
% .0% 4.5% 2.4% 
No 
No 52 26 78 
% 88.1% 38.8% 61.9% 
oligohydramnios 
No 2 6 8 
% 3.4% 9.0% 6.3% 
  
Preterm delivery 
No 2 13 15 
% 3.4% 17.9% 11.1% 
Total 
No 59 67 126 
% 100.0% 100.0% 100.0% 
 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE XII 
PREVALANCE OF LOW BIRTH WEIGHT IN THE STUDY GROUP 
 
Low Birth weight 
Total 
Yes No 
Adequate 
Adequate 
No 8 51 59 
% 13.6% 86.4% 100.0% 
Inadequate 
No 15 52 67 
% 22.4% 77.6% 100.0% 
Total 
No 23 103 126 
% 18.3% 81.7% 100.0% 
 
Chi square value 1.639 
Df= 1 
Sig value= 0.147 
P value= >0.01 
This table shows that 13.6% of our patients in the adequately treated group 
delivered low birth weight babies while 22.4% of patients in the inadequately treated 
group delivered low birth weight babies. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
This study was conducted in PSG Institute of Medical Sciences and Research 
during the period of  March 2011 to August  2012. 
 
The purpose of the study was to follow the pregnancy outcomes in pregnant 
women with hypothyroidism  to see whether they developed complications if left 
untreated and  if adequate treatment  altered the occurrence of complications. 
 
The  total number of pregnant women included in this study were 126.All 
women with diagnosed hypothyroidism  and started on treatment delivering  over a 
period of 1 1//2 yrs were taken consecutively. 
 
All antenatal women were screened using TSH at their first booking visit. 
Those who had an elevated TSH levels, were further tested with FT4 and started on 
treatment with levothyroxine irrespective of  whether FT4  was elevated or not. The  
cut-off level for TSH was taken as 3mIU/ml. Serum thyrotropin (TSH) level in early 
pregnancy is decreased because of thyroid stimulation from the weak TSH effects of 
HCG. In a study by Green WL in 2005, truly normal range of TSH is defined as 0.5-
2.5mIU/ml(6).    So adequate replacement therapy should be given when TSH is  
above 3mIU/ml and/or with low T4, FT4 in pregnancy. 
Patients with TSH values between 3-5mIU/ml were started on a dose of 
25microgram and those with levels from 5-10mIU/ml were given 
50microgram.Those with levels above 10mIU/ml were started on higher doses after 
  
consulting with the endocrinologist. It was not possible for all patients with an 
elevated TSH to undergo further testing with FT4  for many reasons like some being 
already started on treatment if they had already been diagnosed preconceptionally or 
if they had been started on treatment even before FT4 levels were available. So, a 
classification of these patients into a subclinical hypothyroid group and overt 
hypothyroid group was not possible. 
 
TSH levels were repeated for these patients 4-6 weeks after initiating the 
treatment or atleast in each trimester and thyroxine dosage titrated accordingly. Based 
on whether they were started on treatment before 10 weeks and given prompt dosage 
titration, they were grouped as those receiving adequate treatment and inadequate 
treatment. A patient was considered to have received adequate treatment if the repeat 
TSH values were less than 3 mIU/ml Both the groups were followed till delivery and 
closely observed for  the development of complications. 
 
Out of the 126 patients studied, 59 patients were adequately treated,while  67 
patients received inadequate treatment. Out of the 59 adequately treated patients only 
7 developed complications(11.9%).But 43 out of the 67 patients receiving inadequate 
treatment  developed complications(64.2%).   
 
Thyroid hormone is essential for normal development of the placenta. There is  
evidence  that preeclampsia, placental abruption and preterm labour are causally  
  
linked to faulty early placentation. Hypothyroid mothers are also at an increased risk 
of developing fetal growth restriction and delivering low birth weight babies.(12) 
 
The results of our study revealed that gestational diabetes.GDM was found in 
12 out of the 126 hypothyroid patients(9.5%).Overt diabetes was also found in 2 
patients. showing a possible relationship between hypothyroidism and glucose 
intolerance9quote incidence in gen popln). 
 
Approximately 12-15% of clinically recognised pregnancies, end in 
spontaneous miscarriage (24). In our study the prevalence of blighted ovum was 
1.5% and missed abortion was 4.5%and 3% had incomplete abortion in the 
inadequately treated group in our study. Put together the overall miscarriage rate was 
9% which is actually lower than that of its expected occurrence.  It was also noted 
that in our study group , the women who had miscarriages had higher TSH  values at 
diagnosis(>5mU/L). 
 
Preeclampsia is identified in 3.9% of all pregnancies (48) .The prevalence of 
pregnancy induced hypertension (gestational hypertension and preeclampsia) was 
14.9% in the group which was inadequately treated in our study. Davis et al 1988 
followed 25 hypothyroid women through 28 pregnancies who were divided into two 
groups, of which 16 were clinically hypothyroid and 12 had subclinical 
hypothyroidism. This study showed that mothers with overt hypothyroidism are more 
at risk for preeclampsia.  
  
 
Inadequately treated hypothyroid women in our study had 9% pregnancies 
complicated by Oligohydramnios which was higher than its  expected occurrence in 
late pregnancies(3.9%) in the general population. 
 
In our study population 20.9% of pregnancies ended up in preterm delivery 
(delivery before 37 weeks of gestation) which was similar to the outcome of  a study 
done by Jones WS et al in the American Journal of Obstetrics and Gynaecology in 
1969 who concluded  that premature deliveries were more frequent in pregnant 
women who had low thyroxine levels. 
 
In our study 7.4% of the foetuses of inadequately treated mothers had 
intrauterine growth restriction which was almost similar to its occurrence in the  
general population.(3-10%) 
 
Out of the 67 inadequately treated patients in our study, 15 women delivered 
babies with low birth weight (22.4%), whereas, only 8 women in the adequately 
treated group had low birth weight babies (13.6%). But, Low birth weight among 
these babies was mainly attributed to prematurity. 
 
There was no case of placental abruption in the inadequately treated patients in 
my study although Casey Brian et al in 2005 in their study concluded that 
pregnancies complicated by subclinical hypothyroidism had a 3 fold increased risk of 
  
developing  placental abruption and 2 fold increased risk of preterm labour  
compared to euthyroid women . 
 
 
 
 
                                
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
Thyroid hormone is essential for early placental development in pregnancy. 
Especially during the first twelve weeks of pregnancy the fetus entirely depends upon 
the the maternal thyroid hormone for the normal neural and skeletal development. 
Hence early diagnosis and adequate treatment of maternal hypothyroidism in 
pregnancy is essential in decreasing the incidence of complications like abortion, pre 
eclampsia, IUGR, placental abruption, oligohydramnios and low birth weight which 
are associated with hypothyroidism. 
Inadequately treated hypothyroid women in my study group had a 3 fold 
increased risk of developing  preeclampsia. 
 
There was no significant increase in the incidence of abortion or fetal growth 
restriction in the inadequately treated group. 
 
The incidence of GDM in my study is 10.5% 
 
There was no case of placental abruption in my study group. 
 
Oligohydramnios was found to occur more commonly in the inadequately 
treated group. 
 
Adequate treatment  significantly reduced certain complications like pre 
eclampsia,  
  
PROFORMA 
Name: 
Age: 
OP.NO: 
IP.NO: 
Obstetric score: 
H/O Infertility:Yes/No 
Gestational Age at diagnosis: 
Gestational Age at which treatment was started: 
Drug &Dosage used: 
 At diagnosis After treatment 
TSH   
fT4   
 
Previous pregnancy: 
(any significant past H/O) 
 
Present Pregnancy: 
(any antenatal complications) 
 
Gestational age at delivery: 
 
Mode of delivery: 
  
 
Baby details: 
 
Birth weight- 
 
APGAR-      
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CONSENT FORM 
 
I, Mrs.________________________________ aged ________  years have been 
adequately well explained in the language that I understand regarding the clinical 
screening and blood investigations that are to be carried out with me. The purpose of 
the study was explained to me prior to this study being done in detail. I understood 
that the confidentiality will be maintained regarding identity. I have been well 
explained and willing to undergo oral thyroxine supplementation therapy. 
 
After understanding the basis of this study, I give my full consent to the study. 
 
 
Name of the patient: 
Signature of the patient: 
Date and Time: 
 
 
 
Name of the investigator: 
Signature: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
KEY TO MASTER CHART 
 OBSTRETIC SCORE 
 1. PRIMI PARA 
 2. MULTI PARA 
GESTATIONAL AGE AT DIAGNOSIS 
1. PRECONCEPTIONAL 
2. LESS TAHN 10 WEEKS 
3. MORE THAN 10 WEEKS 
TSH AT DIAGNOSIS 
1. 3-5 mIU / ml 
2. 5-10 mIU / ml 
3. MORE THAN 10 mIU / ml 
ADEQUACY OF TREATMENT 
1. ADEQUATE 
2. INADEQUATE 
GESTATIONAL AGE AT DELIVERY 
1.LESS THAN 37 WEEKS 
2.MORE THAN 37 WEEKS 
BIRTH WEIGHT 
1.LESS THAN 2.5Kgs 
2.MORE THAN 2.5Kgs 
 
 
Age No of 
responde
nts
Percenta
ge
Below 20 
yrs
1 7.14
20-25 yrs 4 28.57
26-30 yrs 7 50
Above 
30 yrs
2 14.28
Total 14 100
1
2
3
4
5
6
7
Age
Obs 
Score
No of 
responde
nts
Percenta
ge
Primi 7 50
G2A1 3 21.42
G3P1L1A
1
2 14.28
G3A2 1 7.14
G2P1L1 1 7.14
Total 14 100
0
Below 20 yrs 20-25 yrs 26-30 yrs Above 30 yrs
0 2 4
Primi
G2A1
G3P1L1A1
G3A2
G2P1L1
Obsetric score
Adequate 
or 
Inadequa
te
No of 
responde
nts
Percenta
ge
Adequate 8 57.14
Inadequa
te
6 42.86
Total 14 100
Adequate or Inadequate
Above 30 yrs
6 8
Adequate
Inadequate
 v Name OP Number Age Obsscore Gest age at diagnosisTSH FT4 Rx
1 Vaishnavi 22 2 1 2 1.04 Thyroxine 25 mg       
2 Selvinandhu 29 1 3 2 10.8 Thyroxine 25mg              
3 Revathy 28 1 3 3 Thyroxine 100mg             
4 Epseba 28 1 2 2 No Rx                 
5 Subbulakshmi 35 1 1 2 Thyroxine 25mg              
6 Dhanalakshmi 25 2 2 2 Thyroxine 25 mg       
7 Hemapriya 19 1 1 2 No Rx                 
8 madhavi 23 2 3 2 Thyroxine 50 mg             
9 Ambika 27 1 3 3 1.9 Thyroxine 100mg             
10 Indhu 32 2 3 2 Thyroxine 50 mg       
11 Subashini 26 2 2 2 Thyroxine 50 mg       
12 Christy bai 30 2 2 3 Thyroxine 50 to 125 mg
13 Arthee Ragunathan 30 1 3 2 Thyroxine 50 mg       
14 Saranya 25 2 2 2 Thyroxine 25 mg       
15 Nithya devi O11033610 28 2 1 2 Thyroxine 50 mg       
16 Pandeeshwari O09094688 24 1 3 1 Thyroxine 100 mg      
17 Deepa O11060899 29 2 1 3 No Rx                 
18 Latha O10102270 38 1 3 3 0.62 Thyroxine 100 mg      
19 Yamuna O11094850 32 2 1 3 Thyroxine 100 mg      
20 Thenmozhi O10069730 28 2 2 3 1.3 Thyroxine 50 mg       
21 Sasikala O11008964 24 1 1 2 Thyroxine 12.5 mg           
22 Rajeswari O07020200 25 2 2 2 Thyroxine 25mg              
23 Amutha bharathi O07033914 33 2 1 2 No Rx                 
24 Suji kumari O11030574 38 1 2 2 Thyroxine 25mg              
25 Thulasi mani O10058981 34 2 3 2 No Rx                 
26 Anitha O11001543 26 1 1 2 Thyroxine 12.5 mg           
27 Vasavi O11013245 28 2 2 2 0.9 Thyroxine 25mg              
28 Janani O11024853 26 1 1 2 No Rx                 
29 Renukadeepa O11051733 28 1 1 3 Thyroxine 50 mg             
30 Usha nandhini O11043550 30 2 2 2 2.16 Thyroxine 100mg             
31 Kalaiselvi O10107140 29 1 3 2 Thyroxine 50 mg       
32 Anitha O11063379 25 1 2 3 Thyroxine 100 mg      
33 Akilandam O09068082 25 2 3 2 Thyroxine 100 mg      
34 Dr. Vasanthi O05032611 37 2 3 3 Thyroxine 100 mg      
35 suganthi O11087136 28 1 1 2 Thyroxine 50 mg       
36 ramya O12002464 27 2 2 1 Thyroxine 12.5 mg     
37 hadlin vinothini O11039561 28 1 1 1 0.92 Thyroxine 100 mg      
38 jayamani O08002895 33 2 1 2 No                    
39 kalpana O10038695 27 1 2 1 0.9 Thyroxine 25 mg       
40 rani O11042200 29 2 3 1 Thyroxine 50 mg       
41 gokila O11048831 25 2 2 1 1.07 Thyroxine 25 mg       
42 priskilal O11051692 26 1 3 2 1.1 Thyroxine 25 mg       
43 nagalakhmi O09007892 26 2 3 2 0.9 Thyroxine 50 mg       
44 banumathi O11005533 28 1 1 2 no                    
45 sridevi O11058613 24 2 2 2 0.94 Thyroxine 50 mg       
46 shobana I11005719 28 1 2 2 no                    
47 nandhini O11083592 19 1 1 2 0.95 Thyroxine 75 mg       
48 bharathi devi O11044560 25 2 1 2 Thyroxine 25 mg       
49 karthika O12003418 24 1 2 2 1 Thyroxine 25 mg       
50 roslin O11049542 39 1 2 2 Thyroxin              
51 ramila O11097025 29 2 1 3 no                    
52 gowri O11070363 21 1 1 2 Thyroxine 25 mg       
53 sasirekha O07042238 31 2 2 2 1.2 Thyroxine 50 mg       
54 nandhini O11047851 18 1 1 3 1.19 Thyroxine 25 mg       
55 jamuna O11056277 19 1 1 2 0.9 Thyroxine 25 mg       
56 sathyavani O11076207 34 1 2 2 Thyroxine 150 mg      
57 Selvi O11083866 33 1 3 2 0.8 no                    
58 gowri O11057039 29 2 1 2 Thyroxine 100 mg      
59 vinotha O12006657 21 2 2 3 1.2 Thyroxine 150 mg      
60 adhilakshmi O11064036 22 2 3 3 Thyroxine 25 mg       
61 antony tersa O11083290 30 1 2 2 0.96 Thyroxine 100 mg      
62 kavitha O11069776 23 2 2 3 0.91 Thyroxine 25 mg       
63 nithya           O11062816 23 1 1 2 no                    
64 vidya O11070400 22 1 1 2 1.12 Thyroxine 25 mg       
65 priya O11041832 23 2 2 2 Thyroxine 25 mg       
66 kalpana O11044496 29 2 1 2 Thyroxine 50 mg       
67 manju jancy O11022028 27 1 3 2 Thyroxine 25 mg       
68 Dhanalakshmi O06046895 32 2 3 2 Thyroxine 75 mg       
69 meena O08018408 27 2 3 3 Thyroxine 25 mg       
70 leema O11055688 32 2 3 3 Thyroxine 100 mg      
71 sudha O07041575 28 1 2 2 Thyroxine 50 mg       
72 anitha O08015422 26 2 3 3 Thyroxine 100 mg      
73 shyni O11075075 30 2 2 2 2.3 Thyroxine 50 mg       
74 jennathul O0804588 22 2 1 2 Thyroxine 50 mg       
75 rabiya O08039005 27 2 3 2 Thyroxine 250 mg      
76 vijayalakshmi O11079382 28 1 3 2 Thyroxine 50 mg       
77 ambika devi O11083770 35 1 3 2 Thyroxine 100 mg      
78 kavithamani O11026822 25 2 3 2 Thyroxine 75 mg       
79 shalini O11046688 27 1 2 2 Thyroxine 25 mg       
80 vanitha O11036955 26 2 1 2 Thyroxine 25 mg       
81 dharani O09069139 25 2 1 3 Thyroxine 50 mg       
82 deepa O11035331 21 1 2 2 1.02 Thyroxine 100 mg      
83 shobana O11050897 19 1 1 2 Thyroxine 25 mg       
84 geetha O11032180 28 2 3 1 1.06 Thyroxine 50 mg       
85 ananthi O08037124 30 2 3 2 Thyroxine 50 mg       
86 lavanya O11030700 21 1 2 2 Thyroxine 50 mg       
87 saraswathi O10057417 26 2 1 2 Thyroxine 50 mg       
88 ameena O11062159 28 2 2 2 Thyroxine 25 mg       
89 sarmila O11093663 30 2 3 2  no                     
90 mahalakshmi O11041761 32 2 2 2 Thyroxine 25 mg       
91 Uma Maheshwari   O12041431 26 1 1 1 Thyroxine 25 mg       
92 Thangalakshmi    O12051864 27 1 1 2 Thyroxine 25 mg       
93 Kayalvizhi       O11085962 26 2 1 2 Thyroxine 25mg              
94 Angeline         O11088064 26 1 1 2 Thyroxine 25 mg       
95 Umadevi          O12024847 23 1 2 2 no
96 Manimegalai      O11094144 32 1 1 2 Thyroxine 25mg
97 Catherine jona   O11090367 27 2 3 2 Thyroxine 150mg
98 Ramathilagam       O11078403 26 2 1 2 Thyroxine 25mg
99 Tamilselvi       O11082251 29 2 3 2 Thyroxine 25mg
100 Sanjitha         O11012370 26 2 1 2 Thyroxine 25mg
101 Srividya         O12032626 23 1 3 2 Thyroxine 75mg
102 Manjula          O12003484 31 2 2 2 Thyroxine 75mg
103 Jothi            O12040865 29 2 3 2 Thyroxine 75mg
104 Maleswari        O11031696 22 1 1 2 Thyroxine 25mg
105 Nithyadevi       O12014102 21 1 2 2 Thyroxine 100mg
106 Jenifer          O12000192 23 1 2 3 Thyroxine 50mg
107 Thangamani       O09103105 22 2 3 2 Thyroxine 100mg
108 Nilofer          O12042981 25 1 2 2 Thyroxine 100mg
109 Priya            O07049300 22 1 1 2 Thyroxine 25mg
110 Kavitha          O12045806 27 1 2 3 no             
111 Subashini        O09045097 26 1 2 2 Thyroxine 25mg
112 Sumathi          O07083900 34 2 1 2 Thyroxine 100mg
113 sathyapriya      O08090325 24 2 2 2 Thyroxine 25mg
114 Jeevitha         O11059073 25 2 2 2 Thyroxine 100mg         
115 Arasi            O11075271 26 1 2 2 Thyroxine  25mg         
116 Sathyabala       O08027280 29 2 1 2 Thyroxine 100mg
117 Sukumari laxman  O10095890 33 1 1 2 Thyroxine 25mg
118 Vimala            O12029430 33 1 3 2 Thyroxine 25mg
119 Priya            O09071039 31 2 2 2 Thyroxine 25mg         
120 Kavitha          O09070205 27 2 2 2  Thyroxine 50 mg                    
121 Hemalatha        O11081015 21 1 1 2 Thyroxine 100mg
122 Baby             O10062614 34 2 3 2 Thyroxine 50mg
123 Abirami          O11082925 24 1 2 2 no             
124 Selvi            O11071578 21 1 1 2 Thyroxine 25mg
125 Sofia            O12035614 26 1 2 2 Thyroxine 25mg                 
126 Anitha rajan     O08046404 25 1 1 2 Thyroxine 25mg
Rpt TSH Ade/Inade Complication Other comorbidities Mode of delivery GA at del Birth weight
3.63 1 No                            Nil                    Emergency LSCS                2 2
1 No                            Nil                    NVD                         2 2
3.2 1 No                            Nil                    Emergency LSCS                2 2
2 IUGR Absent diast flow        Nil                    Emergency LSCS                2 2
1 No                            GDM on diet            Vacuum                        2 1
3.36 2 No                            Encerclage             NVD                         2 2
2 IUGR Absent diast flow        NVD                         2 2
3.5 1 No                            Nil                    NVD                         2 2
0.23 1 No                            Rh negative            NVD                         2 2
3.7 1 No                            Nil                    Emergency LSCS                2 2
1.6 2 PPROM                         GDM on diet            Preterm delivery              1 1
2.34 2 No                                                   NVD                         2 2
2.8 1 No                                                   Emergency LSCS                2 2
2 Severe Preeclampsia                                  Preterm delivery              1 1
2.7 1 No                            nil                    Emergency LSCS                2 1
2 PIH                                                  NVD                           2 2
2 Missed abortion                       
3.1 2 PROM                         nil                    Emergency LSCS                2 2
2 Emergency LSCS                2 2
2.3 2 Severe Preeclampsia           nil                    Emergency LSCS                2 2
9.5 2 No                            GDM on diet            Emergency LSCS                2 2
4 2 No                            no                     Vacuum                        2 2
2 Incomplete abortion                                                
0.4 2 Oligohydramnios Rh negative            Emergency LSCS                2 2
2 Missed abortion                                                                   
1 No                                                   NVD                           2 1
6.9 2 No                                                   Emergency LSCS                2 2
2 Incomplete abortion                                                              
1 No                                                   NVD                         2 2
0.56 2 PROM                                                Emergency LSCS                2 2
1 No                                                   NVD                         2 2
5.2 2 IUGR Absent dicst flow                           Emergency LSCS                2 2
0.27 1 No                                                   Elective LSCS 2 2
2.2 1 No                                                   Elective LSCS 2 1
1.2 2                                     Preterm delivery              1 1
1 No                                                   NVD                           2 2
1.34 1 No                                                   NVD                           2 2
6 2 No                                                   Vacuum                        2 2
2.2 1 No                                                   NVD                           2 2
1 No                            Nil                    Elective LSCS 2 2
3.14 1 PROM                         Anemia corrected NVD                           2 2
2.3 2 PPROM                         Preterm delivery              1 1
9.2 2 Blighted ovum                 Rh negative                         
2 PROM                                                Emergency LSCS                2 2
2 No                            TPO +ve                Emergency LSCS                2 2
2 Missed abortion                                                              
3.2 1 No                                                   NVD                           2 2
2.6 1 No                                                   NVD                           2 2
2 No                                                   Vacuum                        2 2
2 PIH, impaired GCT                    Emergency LSCS                2 2
1 No                            Anemia corrected Emergency LSCS                2 2
2 No                            no                     Elective LSCS               2 2
2 PIH                           seizure disorder Elective LSCS               2 2
2.5 1 No                                                   NVD                           2 1
2.2 1 PROM                                                NVD                           2 2
3.2 2 Oligohydramnios                        Emergency LSCS                2 2
2 Oligohydramnios                        Emergency LSCS                2 2
2 No                                                   Elective LSCS               2 2
2 No                            GDM on insulin pre.LSCS NVD                           2 2
2.6 1 No                            Emergency LSCS                2 2
2 Impaired GCT                             NVD                           2 2
9 1 PROM                           Prev LSCS                   Emergency LSCS                2 2
1 No                                                   Emergency LSCS                2 2
3.2 2 No                            GDM on diet            Emergency LSCS                2 2
2 PROM                         NO                     Vacuum                        2 2
6.3 1 Chronic                       GDM on insulin Emergency LSCS                2 2
1 No                            GDM on diet            NVD                           2 2
2.9 2 No                                                   Preterm delivery              1 1
13.6 1 No                                                   NVD                           2 2
2 No                            GDM on diet            NVD             2 2
4.1 1 2nd trimester abortion                                            
1 No                                                   NVD                           2 2
2 No                                                   Elective LSCS                    2 2
3.98 1 Severe Preeclampsia                                  NVD                           2 1
2 Oligohydramnios                        Preterm delivery              1 1
4.2 1 Oligohydramnios Overt DM Preterm delivery              1 1
2 No                                                   NVD                           2 2
2.6 1 Oligohydramnios                        Vacuum                        2 2
2 No                                                   NVD                           2 2
1.35 1 No                                                   Vacuum                        2 2
1 No                                                   NVD                           2 2
2 No                                                   Vacuum                        2 2
1 No                            chronic HW Rh          NVD                           2 2
1.95 1 No                                                   Preterm delivery              1 1
2.56 1 No                            no                     NVD                           2 2
3.5 2 PPROM                         no                     Preterm delivery              1 1
3.9 2 No                                                   Elective LSCS               2 2
5.3 2 PIH                           GDM on diet            Vacuum                        2 1
2 PROM                         GDM on insulin         Vacuum                        2 2
3.3 2 No                            GDM on insulin         Preterm delivery              1 1
1 No                                                   NVD                           2 2
1 No                                                   NVD                           2 2
1 No                                                   NVD                           2 2
1 No                                                   Vacuum                        2 2
2 No                                                   NVD                           2 1
1 No                                                   Vacuum                        2 2
1 No                                                   Vacuum                        2 2
1 No                                                   Elective LSCS 2 2
2 PPROM                                                Preterm delivery              1 1
2 No                                                   Preterm delivery                         1 1
1 No                                                   Elective LSCS 2 2
2 oligohydramnios                        Emergency LSCS                2 2
1 No                                                   Elective LSCS 2 2
1 No                                                   Emergency LSCS                2 2
2 No                                                   Emergency LSCS                2 2
2 No                                                   Vacuum                        2 2
2                                    Preterm delivery              1 1
2 PPROM                         Chronic HTN            Preterm delivery              1 1
1 No                                                   Emergency LSCS                2 2
2 Severe Preeclampsia                                  Emergency LSCS                2 2
2 PIH                                                  Emergency LSCS                2 2
1 No                                                   NVD                           2 2
2 No                                                   NVD                           2 2
2 PIH                                                  NVD                           2 2
2 No                                                   NVD                           2 2
1 No                                                   Elective LSCS 2 2
1 No                            Rh -ve Cervical fibroid Elective LSCS 2 2
1 No                            Overt DM,short stature Elective LSCS 2 2
2 oligohydramnios                                      NVD                           2 2
 Thyroxine 50 mg                    2 IUGR                        Elective LSCS 2 2
1 No                            GDM on insulin         Forceps delivery              2 2
1 No                                                   NVD                           2 2
2                                     NVD                           2 2
1 No                                                   NVD                           2 2
Thyroxine 25mg                 2 PPROM                                                Preterm delivery              1 1
1 No                            Rh -ve                 Emergency LSCS                2 2
